1% Steps Savings Estimates (in 2025)

	Author(s)	Approximate savings in 2025 ($B)[1]	Savings as a percent of NHE (%)	Categorized savings: Medicare spending	Categorized savings: Medicaid spending	Categorized savings: Private health insurance spending	Categorized savings: Prescription drug spending	Categorized savings: Veterans Affairs health spending
Up to $5B in savings								
Expanding convenient access to the flu vaccine for young children	Anderson	**$0.5B**	0.01%					
Expanding kidney exchange	Agarwal, Ashlagi, Rees & Roth	**$1.0B**	0.02%	$1.0B (0.09%)				
Matching post-acute care to clinical need: reducing unnecessary skilled nursing facility use	Werner	**$1.5B**	0.03%	$1.5B (0.14%)				
Implementing episode-based payment for perinatal care in the Medicaid and commercial markets (commercial estimate only)	Carroll	**$1.5B**	0.03%			$1.5B (0.1%)		
Shifting Medicaid nursing home payment toward upfront, episode-based reimbursement	Hackmann	**$2.0B**	0.03%		$2.0B (0.19%)			
Promoting preferred pharmacy networks	Starc & Swanson	**$2.0B**	0.04%				$2.0B (0.40%)	
Reforming home health coverage to reduce fraud	Lee & Skinner	**$1.0B – $4.0B**	0.07%	$4.0B (0.32%)				
Long-term care hospitals: a case study in waste	Einav, Finkelstein & Mahoney	**$4.5B**	0.08%	$4.5B (0.39%)				
Removing all financial disincentives to living kidney donation	Macis	**$1.5B – $5.0B**	0.08%	$5.0B (0.40%)				
Up to $10B in savings								
Paying for family caregiving in long-term care insurance	Mommaerts	**$5.0B**	0.09%		$5.0B (0.52%)			
Reforming the Orphan Drug Act	Chandra	**$8.0B**	0.14%				$8.0B (1.6%)	
Up to $20B in savings								
Paying for biologic PADs in Medicare Part B	Scott Morton & Cooper	**$3.0B – $12.0B**	0.21%	$12.0B (1.0%)				

Health Care Affordability Lab at Yale

1% Steps for Health Care Reform

	Author(s)	Approximate savings in 2025 ($B)[1]	Savings as a percent of NHE (%)	Categorized savings: Medicare spending	Categorized savings: Medicaid spending	Categorized savings: Private health insurance spending	Categorized savings: Prescription drug spending	Categorized savings: Veterans Affairs health spending
Ending pay-for-delay patent litigation settlements in the pharmaceutical industry[2]	Drake & McGuire	**$3.5B – $13.5B**	0.24%				$13.5B (2.6%)	
Eliminating the Medicare Advantage Star Ratings system[3]	Chernew	**$11.5B – $14.5B**	0.25%	$14.5B (1.2%)				
Improving auto-assignment in Medicaid managed care	Ndumele & Wallace	**$6.0B – $15.0B**	0.27%		$15.0B (1.5%)			
Integrating individual and small group health insurance markets to reduce premiums and administrative costs	Dickstein	**$11.0B – $16.5B**	0.29%			$16.5B (0.93%)		
Up to $50B in savings								
Authorizing the VA to recover payments from Medicare Advantage plans for dually enrolled veterans' care	Trivedi, Yoon, Meyers, Schwartz, Brown & Kizer	**$26.5B**	0.47%					$26.5B (22%)
Expanding site-neutral payments in Medicare and addressing anticompetitive vertical integration of physicians[4]	Cooper	**$15.0B – $33.0B**	0.58%	$7.0B (0.59%)		$26.0B (1.45%)		
Less is more: structuring choice for health insurance plans	Abaluck & Gruber	**$35.5B**	0.62%	$10.5B (0.89%)		$24.5B (1.4%)		
Addressing hospital concentration and rising consolidation in the United States[5]	Cooper & Gaynor	**$7.5B – $38.5B**	0.68%			$38.5B (2.2%)		
Designing smart commercial insurer networks	Gruber	**$46.5B**	0.82%			$46.5B (2.6%)		
Up to over $50B in savings								
Real-time adjudication for health insurance claims	Orszag & Rekhi	**$70.0B**	1.2%			$70.0B (3.9%)		
Capping provider prices and price growth in the US commercial health sector[6]	Chernew, Dafny & Pany	**$103.5B**	1.8%			$103.5B (5.8%)		
Total, all 23 briefs[7]		**$256.0B–$460.5B**	**4.5%–8.1%**	**$60.5B (5.0%)**	**$22.0B (2.2%)**	**$327.5B (18%)**	**$23.5B (4.5%)**	**$26.5B (22%)**

Table Notes

1. Estimates are rescaled from each brief's base year to 2025 using CMS's NHE projections and CBO's baselines and rounded to the nearest $500 million.
2. CBO estimated savings to the federal government from a similar policy, https://www.cbo.gov/publication/60083; and the FTC estimated savings to drug purchasers from this policy, https://www.ftc.gov/reports/pay-delay-how-drug-company-pay-offs-cost-consumers-billions-federal-trade-commission-staff-study.
3. CBO estimated savings to the federal government from this policy, https://www.cbo.gov/budget-options/2018/54737.
4. CBO estimated savings to the federal government from a similar policy, https://www.cbo.gov/budget-options/60908.
5. CBO analyzed a similar policy, https://www.cbo.gov/publication/58541; and RAND estimated total savings from this policy, https://www.rand.org/pubs/research_reports/RRA805-1.html.
6. CBO analyzed this policy, https://www.cbo.gov/publication/58541; RAND estimated total savings from this policy, https://www.rand.org/pubs/research_reports/RRA805-1.html; and the Urban Institute estimated total savings from this policy, https://www.urban.org/research/publication/estimates-implications-public-option-and-capped-provider-payment-rate-reforms.
7. The range of potential savings for each policy is reported where calculated by the authors. The lower end of total potential savings uses the lower end of the range for each policy where available, and counts only the largest estimate within each set of policies acting on the same spending.